A panelist discusses how identifying intermediate-risk patients, managing disease heterogeneity in non–muscle-invasive bladder cancer, and addressing long-term care needs present key challenges in ...

The therapeutic response rate was 79% at 24 months, which is comparable to the rates seen at 6 months (78%) and 12 months (82%).

“I think there's a lot to be done and combination therapies, other drugs that can be instilled into this device. It's a bright future,” says Siamak Daneshmand, MD. In this video, Siamak Daneshmand, MD ...

"The final rule for 2025 poses several challenges to urology. Lobbying efforts to preserve telehealth access and the CF will continue, perhaps dragging into 2025," write Jonathan Rubenstein, MD, and ...

“What this means for patients is that thiazides remain an important option in the toolkit for preventing kidney stone recurrence,” says Ryan S. Hsi, MD, FACS.

New research better defines the link between cardiovascular disease risk and prevalence of ED per serum ceramide levels.

What are the 5 stages of bladder health? We've talked a little bit about the Man vs Prostate campaign, and it's really important that it's built upon a principle of linguistic determinism. We really ...

Vibegron is the first beta-3 agonist approved for OAB symptoms in men treated for BPH, showing significant symptom improvement. The phase 3 COURAGE trial demonstrated significant reductions in ...

home / case-based-peer-perspectives / optimizing-sequential-therapy-in-metastatic-castration-resistant-prostate-cancer-mcrpc-with-bone ...

The ASPIRE trial showed SURE's noninferiority to URS in stone-free rate for nephrolithiasis treatment. SURE demonstrated superior stone clearance and residual stone volume outcomes, unaffected by ...

“We really want to understand whether by using this beta emitter, together with the combination of cabazantinib and the nivolumab, we're getting better outcomes than we would expect with the doublet ...